Predictive and prognostic factors for gliomas (Q37873473)

24 August 2017

1 reference

title

Predictive and prognostic factors for gliomas (English)

1 reference

24 August 2017

1

François Ducray

1 reference

24 August 2017

Ahmed Idbaih

2

1 reference

24 August 2017

Xiao-Wei Wang

3

1 reference

24 August 2017

Caroline Cheneau

4

1 reference

24 August 2017

Marianne Labussiere

5

1 reference

24 August 2017

Marc Sanson

6

1 reference

24 August 2017

publication date

1 May 2011

1 reference

Expert Review of Anticancer Therapy

24 August 2017

published in

1 reference

24 August 2017

volume

11

1 reference

24 August 2017

issue

5

1 reference

24 August 2017

page(s)

781-789

1 reference

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

24 August 2017

cites work

1 reference

The 2007 WHO classification of tumours of the central nervous system

21 January 2018

1 reference

Glioblastomas with an oligodendroglial component: a pathological and molecular study

21 January 2018

1 reference

Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas

21 January 2018

1 reference

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1

21 January 2018

1 reference

Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma

21 January 2018

1 reference

Oligodendrogliomas: molecular biology and treatment.

21 January 2018

1 reference

A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma

21 January 2018

1 reference

Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas

21 January 2018

1 reference

Allelic loss of chromosome 1p and radiotherapy plus chemotherapy in patients with oligodendrogliomas.

21 January 2018

1 reference

Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.

21 January 2018

1 reference

Genetic markers predictive of chemosensitivity and outcome in gliomatosis cerebri

21 January 2018

1 reference

Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment [...]

21 January 2018

1 reference

Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker?

21 January 2018

1 reference

Dynamic history of low-grade gliomas before and after temozolomide treatment

21 January 2018

1 reference

Diagnostic and prognostic markers in gliomas

21 January 2018

1 reference

1p36 is a preferential target of chromosome 1 deletions in astrocytic tumours and homozygously deleted in a subset of glioblastomas

21 January 2018

1 reference

Two types of chromosome 1p losses with opposite significance in gliomas

21 January 2018

1 reference

Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests mechanism of concurrent 1p and 19q loss

21 January 2018

1 reference

NOTCH2 is neither rearranged nor mutated in t(1;19) positive oligodendrogliomas

21 January 2018

1 reference

Gene amplification is a poor prognostic factor in anaplastic oligodendrogliomas

21 January 2018

1 reference

BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas.

21 January 2018

1 reference

Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study

21 January 2018

1 reference

Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors.

21 January 2018

1 reference

Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile

21 January 2018

1 reference

Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis

21 January 2018

1 reference

alpha-Internexin expression identifies 1p19q codeleted gliomas.

21 January 2018

1 reference

MGMT gene silencing and benefit from temozolomide in glioblastoma

21 January 2018

1 reference

Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents

21 January 2018

1 reference

Prognostic value of O6-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods

21 January 2018

1 reference

MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma

21 January 2018

1 reference

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

21 January 2018

1 reference

Long-term survival of patients with glioblastoma treated with radiotherapy and lomustine plus temozolomide

21 January 2018

1 reference

MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: a report from EORTC Brain Tumor Group Study 26951.

21 January 2018

1 reference

NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide

21 January 2018

1 reference

Up-front temozolomide in elderly patients with anaplastic oligodendroglioma and oligoastrocytoma.

21 January 2018

1 reference

MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients

21 January 2018

1 reference

MGMT methylation: a marker of response to temozolomide in low-grade gliomas

21 January 2018

1 reference

Identification of regions correlating MGMT promoter methylation and gene expression in glioblastomas

21 January 2018

1 reference

An integrated genomic analysis of human glioblastoma multiforme

21 January 2018

1 reference

Mutational analysis of IDH1 codon 132 in glioblastomas and other common cancers

21 January 2018

1 reference

IDH1 and IDH2 mutations in gliomas

21 January 2018

1 reference

Isocitrate dehydrogenase 1 codon 132 mutation is an important prognostic biomarker in gliomas.

21 January 2018

1 reference

IDH1 mutations as molecular signature and predictive factor of secondary glioblastomas

21 January 2018

1 reference

IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas

21 January 2018

1 reference

Analysis of the IDH1 codon 132 mutation in brain tumors

21 January 2018

1 reference

IDH1 mutations at residue p.R132 (IDH1(R132)) occur frequently in high-grade gliomas but not in other solid tumors

21 January 2018

1 reference

Recurring mutations found by sequencing an acute myeloid leukemia genome

21 January 2018

1 reference

IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study

21 January 2018

1 reference

The common feature of leukemia-associated IDH1 and IDH2 mutations is a neomorphic enzyme activity converting alpha-ketoglutarate to 2-hydroxyglutarate

21 January 2018

1 reference

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

21 January 2018

1 reference

All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2.

21 January 2018

1 reference

IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

21 January 2018

1 reference

IDH1 mutations in low-grade astrocytomas predict survival but not response to temozolomide

21 January 2018

1 reference

IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas.

21 January 2018

1 reference

IDH1 mutations are present in the majority of common adult gliomas but rare in primary glioblastomas

21 January 2018

1 reference

Glioma-derived mutations in IDH1 dominantly inhibit IDH1 catalytic activity and induce HIF-1alpha

21 January 2018

1 reference

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

21 January 2018

1 reference

Hydroxyglutaric aciduria and malignant brain tumor: a case report and literature review

21 January 2018

1 reference

D-2-hydroxyglutaric acid induces oxidative stress in cerebral cortex of young rats

21 January 2018

1 reference

IDH1 and IDH2 mutations in gliomas.

21 January 2018

1 reference

Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors

21 January 2018

1 reference

A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation

21 January 2018

1 reference

Cancer-associated metabolite 2-hydroxyglutarate accumulates in acute myelogenous leukemia with isocitrate dehydrogenase 1 and 2 mutations

21 January 2018

1 reference

Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age

21 January 2018

1 reference

A multigene predictor of outcome in glioblastoma.

21 January 2018

1 reference

Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology.

21 January 2018

1 reference

Glioma stem cells promote radioresistance by preferential activation of the DNA damage response

21 January 2018

1 reference

Analysis of gene expression and chemoresistance of CD133 cancer stem cells in glioblastoma

21 January 2018

1 reference

Temozolomide preferentially depletes cancer stem cells in glioblastoma

21 January 2018

1 reference

21 January 2018

1 reference

Cancer stem cell analysis and clinical outcome in patients with glioblastoma multiforme.

21 January 2018

1 reference

Oligodendroglioma cell lines containing t(1;19)(q10;p10).

21 January 2018

1 reference

Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer

21 January 2018

1 reference

YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas.

21 January 2018

1 reference

Serum GFAP is a diagnostic marker for glioblastoma multiforme

21 January 2018

1 reference

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1586/ERA.10.202

1 reference

24 August 2017

1 reference